靶向 TIGIT：肝外胆管癌免疫治疗新希望 —— 解读《TIGIT expression in extrahepatic cholangiocarcinoma and its impact on CD8 + T cell exhaustion: implications for immunotherapy》 陆军军医大学第一附属医院肝胆外科的 ...

drugs targeting TIGIT had become sought-after assets in the pharma industry, on the promise that they may inhibit anti-tumour responses that down-regulate the activity of T-cells and provide an ...

Pathogen-fighting immune cells called tissue-resident memory CD8 T cells (TRM cells) go through a surprising transformation -- and relocation -- as they fight infections in the small intestine.

Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint.

This discovery sheds light on how tissue-resident memory CD8 T cells adapt to their location in the body, ensuring a coordinated and effective immune response and how microenvironments and ...

TIGIT靶点，曾被誉为“下一个PD-1”，在免疫治疗领域备受瞩目。然而，其研发之路却充满坎坷，众多药企纷纷折戟。近期，阿斯利康的PD-1/TIGIT双抗药物Rilvegostomig启动了头对头帕博利珠单抗（K药）的III期研究，为TIGIT靶点带 ...

Initial data demonstrate a highly differentiated clinical pharmacodynamic profile with unprecedented levels of selective CD8+ T cell activation as well as initial evidence of anti-tumor effect ...